Final report of a phase II trial of nimotuzumab in the treatment of refractory and relapsed high-grade gliomas in children and adolescents. Hematology Meeting Reports, [S. l.], v. 1, n. 6, 2009. DOI: 10.4081/hmr.v1i6.675. Disponível em: https://journals.pagepress.org/hmr/article/view/675. Acesso em: 10 aug. 2025.